Overview

Cardo Medical Inc. (CDOM)

Cardo Medical was formed in February 2007 when it acquired the assets and operations of Accin Corporation, a product development company founded in 2005. Cardo Medical designs, develops and commercializes innovative orthopaedic implants used in knee, hip and spine surgeries. To date, the company has filed over 27 patent applications in various stages of issuance which covers a broad range of fusion and motion preservation technologies. Cardo Medical has received numerous FDA clearances to market its implant systems and has successfully commercialized it first product release, a uni-compartmental system, which has been used in over 400 surgeries to date with over 2 years of clinical history.

Cardo Medical creates reconstructive orthopedic and spinal surgery products through advanced engineering. Cardo Medical's superior engineering talent closely collaborates with leading surgeons around the country to create products that reduce or eliminate joint pain and allow our patients to achieve active lives. Cardo Medical's cutting edge products are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes.

Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged.

Share Statistics:

Outstanding:	212.5 m
Float:	11.3 m

Important Company Highlights

Proven management team from market leading companies with focus in orthopaedic innovations and product development led by Dr. Andrew Brooks, orthopaedic surgeon and successful serial entrepreneur.

Investment backing with over $13M invested through highly reputable and successful investors and entrepreneurs led by Dr. Phillip Frost, Chairman and CEO of Opko Health and former Chairman and CEO of IVAX.

Completed reverse merger on August 29, 2008 with clickNsettle.com (OTCBB:CKST) with intent to have shares soon listed on AMEX exchange.

Pending profitable operations amidst ongoing robust acquisition and business development activity.

Rich patent portfolio with 27 patent applications in various stages of publication.

Eight (8) FDA 510k regulatory clearances received across knee, hip and spine product portfolio.

Product innovations and value validated through numerous licensing and business developments with market leading orthopaedic implant companies.

Retained surgeon network relationships through key opinion thought leaders, related fellowships and affiliation to surgery centers.

Aging and increasingly active demographics and degenerative diseases support the expanding need for reconstructive orthopaedic and spinal surgery.

Robust product pipeline featuring revolutionary leapfrog developments adapted from orthopaedic and surgical sub-specialties and related technologies.

DISCLAIMER

Certain statements and information included herein constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. The forward-looking statements describe our expectations, plans and intentions about our business, financial condition, results of operations, cash flows and prospects. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied, in or by such forward-looking statements. Such factors include, among other things, the Company's ability to market, commercialize and achieve market acceptance of any of its products or any product candidates that it is developing or may develop in the future, and the acceptance of those products; the Company's ability to maintain an adequate sales network for its products, including its ability to attract and retain independent distributors; the effect on Medicare prescription drug coverage legislation and future legislative or regulatory reform of the health care system and its effect on the Company's ability to sell its products profitably; the Company's business strategy and underlying assumptions about market data, demographic trends, reimbursement trends, pricing trends and trends in the treatment of spine, hip and knee disorders; the Company's estimates regarding anticipated operating losses, future revenue, expenses, capital requirements, liquidity and the Company's potential need to raise additional financing; the Company's ability to comply with industry standards in regulatory compliance matters; the Company's ability to control its costs and achieve profitability; the Company's ability to market and sell its products in any international market that it attempts to enter; the Company's ability to attract and retain a qualified management team, as well as other qualified personnel and advisors; the Company's ability to enter into licensing and business combination agreements with third parties and to successfully integrate the acquired technology and/or businesses; the management team's ability to accommodate growth and manage a larger organization; the Company's ability to protect its intellectual property, and to not infringe upon the intellectual property of third parties; the Company's ability to conclude that it has effective disclosure controls and procedures; the Company's ability to comply with corporate governance programs and with changing regulations concerning corporate governance and public disclosure; and other factors contained in the Company's filings with the Securities and Exchange Commission.

Management Team

Andrew A. Brooks, M.D.
Chairman and CEO

Michael Kvitnitsky
President and COO

Derrick Romine
Chief Financial Officer

Investor Relations Contact

Steve Rubin
Investor Relations
Suite 1500
4400 Biscayne Boulevard
Miami, FL 33137
Phone: (305) 575-6015
Fax:      (305) 575-6444
Email: SR@thefrostgrp.com